Clinical trials located in

Mulhouse

Mulhouse city is located in France. Currently, 8 clinical trials are being conducted in this city.

Mulhouse, nestled in eastern France near the borders with Germany and Switzerland, is a city rich in industrial heritage, particularly in the textile and automotive industries. It is home to the Cité de l’Automobile, which houses the largest collection of Bugatti vehicles. Mulhouse also boasts a vibrant cultural scene, with the Musée de l’Impression sur Étoffes showcasing its history in printed textiles. Despite its industrial roots, the city is adorned with green spaces like the Parc Zoologique et Botanique, blending urban development with natural beauty.

  • CT-EU-00116238

    Study of Selinexor Combined with Ruxolitinib for Myelofibrosis

    This here clinical trial is studying a new combination of drugs for treating myelofibrosis, which is a type of blood cancer. The main drugs being tested are selinexor and ruxolitinib. Selinexor is a new experimental drug that works by blocking the export of certain proteins from the cell nucleus, while ruxolitinib is an approved drug that inhibits JAK enzymes involved in myelofibrosis.

    The trial has two phases. The first phase, which is already completed, looked at finding the safest and most effective doses of selinexor when combined with ruxolitinib. The second phase is where they are actually testing this drug combination in patients with myelofibrosis who have not received any prior JAK inhibitor treatment.

    Patients in this phase will be randomly assigned to receive either the selinexor + ruxolitinib combination, or a placebo plus ruxolitinib alone. The main goals are to see if the combination can reduce spleen size by at least 35% after 24 weeks of treatment, and also improve symptoms like fatigue, itching, and abdominal discomfort by at least 50% on a special myelofibrosis symptom scale. Safety will also be closely monitored throughout the study.

    • Selinexor
    • Ruxolitinib
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    • Lacutamab
    • Oxaliplatine
    • Gemcitabine
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing new drug impact on chronic diabetic peripheral neuropathic pain

    This study focuses on testing a new medicine called GSK3858279 for people living with chronic Diabetic Peripheral Neuropathic Pain that’s not been well-managed. The medicine will be given to some people selected at random, while others will receive a placebo. It’s important that neither the patient nor the doctors will know who received the drug and who got the placebo. The main aim is to check how well GSK3858279 works for nerve pain. Participants will keep track of their pain daily using a simple scale from 0 (no pain) to 10 (worst imaginable pain). These daily scores will then be added up each week. Additionally, any health issues occurring during the study will be closely monitored, regardless of their relation to GSK3858279.

    • GSK3858279- new potential medication for chronic pain associated with osteoarthritis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.